Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2- advanced breast cancer in five European countries.

A, Davie; GC, Carter; A, Rider; J, Pike; K, Lewis; A, Bailey; GL, Price; F, Ringeisen; X, Pivot

doi:10.1186/s12885-020-07294-2

Public

Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2- advanced breast cancer in five European countries.

Shared by NobleBlocks on Sep 7, 2020 • 12:00 AM UTC

Authors:

Davie A

Carter GC

Rider A

Abstract

<h4>Background</h4>Endocrine therapy (ET)-based regimens are the mainstay of treatment for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer. With the introduction of new treatment classes, it is important to examine patient ...

Subject

Advanced breast cancer

Health-related Quality Of Life

Patient-reported Outcomes

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!